ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Canakinumab Study Fails to Meet Primary Endpoint
November 17, 2020Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome. -
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
November 10, 2020Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome.
Pharma Sources Insight January 2025
